Repeat use [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2013-04-24 15:45 (4812 d 20:25 ago) – Posting: # 10488
Views: 16,844

Hi Ohlbe,

❝ I doubt it (...) If, by some sort of a miracle, he decides to make a pharmacovigilance declaration, to which product will he assign the AE?


❝ Sorry for being pessimistic, but I don't have much trust in the pharmaco­vigilance of generics :-(


I agree in the sense that the PV systems -and here I do not mean any applicant's own system but the EU-wide and possibly ROW-wide systems- do not pick up issues with great sensitivity and they rely on active reporting reporting. Only the serious stuff gets reported.
For a repeat use MRP the applicant will be able to refer to something like 1.000.000 patient years of treatment experience and garnish that with info about reported numbers of deaths or people who contracted syphilis while being treated with the drug etc etc. I think that counts for something although it is not formalised.

In a nutshell I would rather take a product that has 1.000.000 or whatever patient years in the luggage and no ISR rather than taking a product with acceptable ISR for which the total human exposure is a 2,2,2-BE trial in Hevo's totalling 1 day of exposure with one unit dose for the Test.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
384 visitors (0 registered, 384 guests [including 26 identified bots]).
Forum time: 12:11 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5